Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
Financial Results:
Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY24 of ₹3,063.00 Crores up from ₹3,001.00 Crore year on year, a rise of 2.07%.
Total Expenses for Q4FY24 of ₹2,859.00 Crores up from ₹2,847.00 Crores year on year, a rise of 0.42%.
Consolidated Net Profit of -₹1,214.00 Crores from -₹403.00 Crores in the same quarter of the previous year.
The Earnings per Share is -₹43.17, from -₹15.18 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.